Journal
MOLECULAR THERAPY-ONCOLYTICS
Volume 3, Issue -, Pages -Publisher
CELL PRESS
DOI: 10.1038/mto.2016.15
Keywords
-
Categories
Funding
- NCI [P30 CA08748, P50 CA086438]
- DOD
- Starr Foundation Tri-Institutional Stem Cell Initiative
Ask authors/readers for more resources
The treatment of cancer patients with autologous T cells expressing a chimeric antigen receptor (CAR) is one of the most promising adoptive cellular therapy approaches. Reproducible manufacturing of high-quality, clinical-grade CAR-T cell products is a prerequisite for the wide application of this technology. Product quality needs to be built-in within every step of the manufacturing process. We summarize herein the requirements and logistics to be considered, as well as the state of the art manufacturing platforms available. CAR-T cell therapy may be on the verge of becoming standard of care for a few clinical indications. Yet, many challenges pertaining to manufacturing standardization and product characterization remain to be overcome in order to achieve broad usage and eventual commercialization of this therapeutic modality.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available